+1,070.0%
TSM vs MRNA
+794.5%
+275.5%
-56.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.8% | -4.8% | +5.7% | +1.1% |
| 7D | -12.3% | -20.9% | +8.6% | -11.2% |
| 30D | -13.7% | -13.3% | -0.4% | -13.2% |
| 3M | -12.1% | +212.6% | -224.6% | -20.6% |
| 6M | -8.0% | +309.0% | -317.0% | -19.2% |
| YTD | +20.3% | +567.3% | -547.0% | +0.5% |
| 1Y | +31.9% | +689.7% | -657.8% | +8.4% |
| 3Y | +279.0% | +157.4% | +121.6% | +231.3% |
| 5Y | +218.4% | -21.7% | +240.1% | +191.6% |
| All | +1,070.0% | +794.5% | +275.5% | +910.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling